Our results demonstrate that CSF1-R expression on carcinoma cells detected by immunohistochemistry provides prognostic information in breast cancers, particularly in a subset of ER-positive cases, and may represent an actionable target for patient selection in trials evaluating CSF-1R blockade. Here, CSF1R is linked to carcinoma.